<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/swiper.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<style type="text/css">
	

	.bodyContent {width:945px;height:445px;}

    .bodyContent > li:first-child {width:315px;height:435px;background-color: #d9e6ec;margin-top:40px;margin-right: 25px;float:left;}
    .bodyContent > li:first-child > :first-child{padding-top: 20px; padding-left: 20px; padding-right: 20px; font-size: 18px; font-family: "interstatelight";}
    .bodyContent > li:first-child> p:last-child{padding-left: 20px; padding-right: 20px; padding-bottom:20px; font-size: 14px; font-family: "interstatelight";}
    
    table{ width:600px;/*height:435px;*/overflow: scroll;background-color: white; margin-top:40px;}
    td {border:1px solid white;}
    tr:first-child {border:1px solid white;}

    .bodyContent > li:nth-child(2) >table > tbody > tr:nth-child(2) > td:first-child {background-color: white;}
    .bodyContent > li:nth-child(2) > table > tbody > tr:first-child > td{ font-family: "interstateregular"; color: #b2d144; text-align: right; font-size: 10px; height: 20px;} 
    .bodyContent > li:nth-child(2) > table > tbody > tr:nth-child(2) > td{ height: 20px; width:175px; text-align: center; background-color: #0c4d72; color: white; font-size: 10px; padding: 5px; 
        font-family: "interstateregular";}
    .bodyContent > li:nth-child(2) > table > tbody > tr:nth-child(2) > td:first-child{ height: 20px; width:220px; text-align: center;}
    
    .bodyContent > li:nth-child(2) > table > tbody > tr:nth-child(3) > td {text-align: center; color: white; background-color:#0c4d72; font-size:10px; padding: 5px; font-family: "interstateregular"; line-height: 13px;}
    .bodyContent > li:nth-child(2) > table > tbody > tr:nth-child(3) > td:first-child{background-color: white;}

    .bodyContent > li:nth-child(2) > table > tbody > tr:nth-child(4) > td { background-color: #b2d144; font-family: "interstateregular"; font-size: 10px; text-align: center;}
    .bodyContent > li:nth-child(2) > table > tbody > tr:nth-child(4) > td:first-child {text-align: left; padding-left: 15px;}

    .bodyContent > li{display:inline-block;}



	
</style> 
</head>
<body>
	<section id="container">
    	<nav class="nav-top icon">
            <ul>
                <li data-href="home"></li>
                <li data-href="warning">Contraindications<br />and Warnings</li>
                <li data-href="pi">PI</li>
                <li data-href="bibliography"></li>
                <li data-href="resource"></li>
                <li data-href="menu"></li>
            </ul>
        </nav>
    	<article class="content">
        	<!--subslides-->
            <div class="swiper-container">
                <ul class="swiper-wrapper">
                	<!-- slide 1-->
                    <li class="swiper-slide" data-slide="1">
                         <h2><span>SAFETY AND TOLERABILITY</span>
                            THE SAFETY AND TOLERABILITY OF LYNPARZA ARE ACCEPTABLE<br />
                            FOR ORAL MAINTENANCE TREATMENT ADMINISTRATION<sup data-ref="3">4</sup>
                        </h2>
                      
                      <ul class="bodyContent">
                        <li>
                            <p>More patients in the olaparib group than in the placebo<br />group had dose interruptions<br />(49 [36%] of 136 vs 21 [16%]<br /> of 128) or dose reductions 57<br />[42%] vs 28 [22%]): vomiting,<br />nausea, and fatigue were the<br />most common causes of dose<br />interruptions or reductions in the<br />olaparib group.3,4</p>
                            <p>Serious adverse events were reported in<br />25 (18%) of 136 patients in the olaparib<br />group and 11 (9%) of 128 patients in<br />the placebo group; the most common<br />serious adverse event was small intestinal<br />obstruction (two [1%] patients in the<br />olaparib group and three [2%] in the<br />placebo group.</p>
                        </li>
                        <li>
                            <table>
                                <tbody>
                                    <tr>
                                        <td colspan="5">OVERALL PATIENT POPULATION</td>
                                    </tr>
                                    <tr>
                                        <td></td>
                                        <td colspan="2">All Grades</td>
                                        <td colspan="2">Grade >3</td>
                                    </tr>
                                    <tr>
                                        <td></td>
                                        <td>Olaparib<br />n=136)</td>
                                        <td>Placebo<br />(n=128)</td>
                                        <td>Olaparib<br />(n=136)</td>
                                        <td>Placebo<br /> (n=128)</td>
                                    </tr>
                                    <tr>
                                        <td>Patients with any AE</td>
                                        <td>132 (97%)</td>
                                        <td>119 (93%)</td>
                                        <td>55 (40%)</td>
                                        <td>28 (22%)</td>
                                    </tr>
                                </tbody>
                            </table>
                        </li>
                      </ul>

                      <!--slide 1
                      <br />
                       
                        
                        <div class="footnote">
                            <strong>Study design:</strong> This a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum- sensitive,
relapsed, high-grade serous ovarian cancer who had received two or more platinum based regimens and had a partial or complete response to their
most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point
was progression-free survival according to the Response Evaluation Criteria in Solid Tumours guidelines. Primary endpoint was PFS. Secondary endpoints
included OS, best overall response, HRQoL, safety and tolerability.
                        </div>-->
                       
                    </li>
                    <!-- slide 2 -->
                    <li class="swiper-slide" data-slide="2">
                         <h2><span>CLINICAL DATA â€“ STUDY OVERVIEW</span>
                           STUDY 19 WAS A RANDOMISED, DOUBLE-BLIND,<br />
                            PLACEBO-CONTROLLED PHASE II CLINICAL TRIAL<sup data-ref="2">2</sup>
                        </h2>
                        <p>In Study 19, Lynparza as maintenance treatment met the primary endpoint of improving PFS in the overall study
                            population.<sup data-ref="2">2</sup></p>
                      slide 2
                    </li>
                    
                </ul><!-- end swiper-wrapper -->
                <!-- Add Arrows -->
       			<span class="swiper-button icon arrow swiper-button-next"></span>
        		<span class="swiper-button icon arrow swiper-button-prev"></span>
            </div>
            
        	<span class="logo lynp"></span>
        </article>
    
    <!-- popup -->
    <div class="overlay">
    	<!-- reference -->
    	<div class="ref hide">
            <div class="item"> <span class="close icon"></span>
                <h1>References</h1>
                <ol></ol>
            </div>
        </div><!-- end ref -->
         <!-- info -->
        <div class="item info hide"><span class="arrow icon"></span>
            <!-- Info contents here! -->
        </div><!-- end info -->
      
       <!-- navigation -->
        <div class="item nav hide"><span class="close icon"></span>
        	<ul class="section">
        		<li data-href="1"><span>Unmet need</span></li>
        		<li data-href="2"><span>Mechanism<br />of action</span>
                	<ul>
                		<li data-href="2"><span>PARPi</span></li>
                		<li data-href="3"><span>DNA repair</span></li>
                	</ul>
                </li>
        		<li data-href="4"><span>Clinical Data</span>
                	<ul>
                		<li data-href="4"><span>Extended PFS</span></li>
                		<li data-href="5"><span>Study overview</span></li>
                		<li data-href="6"><span>BRCAm<br />sub-analysis</span></li>
                		<li data-href="7"><span>TFST<br />Exploratory Analysis</span></li>
                		<li data-href="8"><span>TSST<br />Exploratory Analysis</span></li>
                		<li data-href="9"><span>Overall Survival</span></li>
                		<li data-href="10"><span><em>Post-Hoc</em> interim exploratory analysis of os</span></li>
                		<li data-href="11"><span>Patient Characteristics</span></li>
                	</ul>
                </li>
        		<li data-href="12"><span>BRCAm+</span>
                	<ul>
                		<li data-href="12"><span>BRCAm testing</span></li>
                		<li data-href="13"><span>About BRCAm</span></li>
                		<li data-href="14"><span>Testing<br />guidelines</span></li>
                		<li data-href="15"><span>BRCAm status</span></li>
                	</ul>
                </li>
        		<li data-href="16"><span>Patient<br />Support</span>
                	<ul>
                		<li data-href="16"><span>LYNPARZA Patient&nbsp;Access Programme</span></li>
                		<li data-href="17"><span>Patient&nbsp;Support Programme</span></li>
                		<li data-href="18"><span>Patient<br />Support Kit</span></li>
                		<li data-href="19"><span>Capsule<br />companion</span></li>
                	</ul>
                </li>
        		<li data-href="20"><span>Dosing &amp;<br />administration</span>
                	<ul>
                		<li data-href="20"><span>Safety and<br />tolerability</span></li>
                		<li data-href="21"><span>Dosing</span></li>
                	</ul>
                </li>
        		<li data-href="22"><span>Summary</span></li>
        	</ul>
            
        </div><!-- end nav -->
    </div>

    </section>
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/swiper.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){
		 var mySwiper = new Swiper('.swiper-container', {
        	paginationClickable: true,
        	direction: 'vertical',
			nextButton: '.swiper-button-next',
        	prevButton: '.swiper-button-prev'
		  });
		
		
	})

</script>
</body>
</html>
